Trade Report: The Wedbush Securities Inc. Sold shares of Johnson & Johnson (JNJ)

The Wedbush Securities Inc. Sold shares of Johnson & Johnson (JNJ)

Wedbush Securities Inc. cut its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.5% during the second quarter, Holdings Channel reports. The fund owned 48,175 shares of the company’s stock after selling 219 shares during the period. Johnson & Johnson comprises about 1.0% of Wedbush Securities Inc.’s investment portfolio, making the stock its 11th largest position. Wedbush Securities Inc.’s holdings in Johnson & Johnson were worth $5,844,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Americafirst Capital Management LLC purchased a new position in Johnson & Johnson during the second quarter valued at $101,000. INR Advisory Services LLC purchased a new position in Johnson & Johnson during the second quarter valued at $150,000. Capital Asset Advisory Services LLC purchased a new position in Johnson & Johnson during the second quarter valued at $202,000. NewSquare Capital LLC boosted its position in Johnson & Johnson by 4.9% in the second quarter. NewSquare Capital LLC now owns 1,791 shares of the company’s stock valued at $217,000 after buying an additional 83 shares in the last quarter. Finally, Shayne & CO. LLC purchased a new position in Johnson & Johnson during the second quarter valued at $219,000. 65.32% of the stock is owned by hedge funds and other institutional investors.

Shares of Johnson & Johnson (NYSE:JNJ) traded down 0.385% during midday trading on Friday, hitting $117.805. The company’s stock had a trading volume of 1,992,929 shares. Johnson & Johnson has a 52-week low of $94.28 and a 52-week high of $126.07. The firm has a market cap of $322.30 billion, a P/E ratio of 21.954 and a beta of 0.62. The stock’s 50 day moving average is $118.75 and its 200-day moving average is $117.30.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, July 19th. The company reported $1.74 EPS for the quarter, topping analysts’ consensus estimates of $1.68 by $0.06. The company had revenue of $18.50 billion for the quarter, compared to analysts’ expectations of $17.98 billion. Johnson & Johnson had a net margin of 20.97% and a return on equity of 24.70%. Equities analysts predict that Johnson & Johnson will post $6.69 EPS for the current fiscal year.

Several research analysts recently commented on the company. RBC Capital Markets reissued an “outperform” rating and set a $133.00 price target (up from $125.00) on shares of Johnson & Johnson in a research report on Wednesday, July 20th. Leerink Swann reissued an “outperform” rating and set a $140.00 price target (up from $125.00) on shares of Johnson & Johnson in a research report on Wednesday, July 20th. Royal Bank Of Canada increased their price target on Johnson & Johnson from $125.00 to $133.00 and gave the company an “outperform” rating in a research report on Wednesday, July 20th. BMO Capital Markets reissued an “outperform” rating and set a $132.00 price target on shares of Johnson & Johnson in a research report on Wednesday, July 20th. Finally, Deutsche Bank AG reissued a “hold” rating and set a $142.00 price target (up from $125.00) on shares of Johnson & Johnson in a research report on Thursday, July 21st. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $120.19.

In related news, VP Dominic J. Caruso sold 41,146 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, July 26th. The shares were sold at an average price of $125.01, for a total value of $5,143,661.46. Following the sale, the vice president now owns 157,819 shares of the company’s stock, valued at approximately $19,728,953.19. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Ronald A. Kapusta sold 2,935 shares of Johnson & Johnson stock in a transaction that occurred on Friday, July 22nd. The stock was sold at an average price of $125.01, for a total transaction of $366,904.35. Following the completion of the sale, the chief accounting officer now directly owns 28,660 shares in the company, valued at approximately $3,582,786.60. The disclosure for this sale can be found here. 0.11% of the stock is currently owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

Related posts

Leave a Comment